We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

119 hedge funds and large institutions have $1.15B invested in C4 Therapeutics in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

27% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 33

5% more funds holding

Funds holding: 113 → 119 (+6)

2.62% more ownership

Funds ownership: 71.19% → 73.81% (+2.6%)

25% less capital invested

Capital invested by funds: $1.54B → $1.15B (-$388M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
119
Holders Change
+6
Holders Change %
+5.31%
% of All Funds
1.83%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
22
Increased
42
Reduced
33
Closed
16
Calls
$1.9M
Puts
–
Net Calls
+$1.9M
Net Calls Change
-$2.73M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$24.8M
2
Millennium Management
Millennium Management
New York
+$18.4M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$10.3M
4
BlackRock
BlackRock
New York
+$9.84M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.32M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$18.1M
2
DCM
Driehaus Capital Management
Illinois
-$11.1M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.94M
4
SCM
Soleus Capital Management
Connecticut
-$7.49M
5
First Trust Advisors
First Trust Advisors
Illinois
-$3.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$11M -$2.95M -74,555 -18%
Charles Schwab
27
Charles Schwab
California
$8.52M +$166K +4,199 +2%
PBA
28
Paradigm Biocapital Advisors
New York
$8.33M +$10.2M +258,746 New
CCP
29
Clough Capital Partners
Massachusetts
$8.23M -$3.63M -91,819 -26%
N
30
Nuveen
North Carolina
$7.47M -$1.74M -43,934 -14%
Goldman Sachs
31
Goldman Sachs
New York
$7.24M -$1.55M -39,116 -15%
EC
32
EcoR1 Capital
California
$6.44M – – –
Citadel Advisors
33
Citadel Advisors
Florida
$5.21M +$4.81M +121,621 +302%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$4.04M +$509K +12,873 +11%
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$4.03M – – –
TD Asset Management
36
TD Asset Management
Ontario, Canada
$3.42M +$261K +6,600 +7%
AllianceBernstein
37
AllianceBernstein
Tennessee
$3.3M +$845K +21,370 +26%
Bank of America
38
Bank of America
North Carolina
$3.27M +$3.17M +80,122 +372%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$2.96M +$1.3M +32,956 +56%
Citigroup
40
Citigroup
New York
$2.66M +$621K +15,712 +24%
Walleye Capital
41
Walleye Capital
New York
$2.63M +$3.23M +81,720 New
Voloridge Investment Management
42
Voloridge Investment Management
Florida
$1.96M -$1.76M -44,411 -42%
Deutsche Bank
43
Deutsche Bank
Germany
$1.8M +$1.26M +31,854 +132%
Bank of Montreal
44
Bank of Montreal
Ontario, Canada
$1.78M +$2.14M +54,100 New
BG
45
Bellevue Group
Switzerland
$1.52M – – –
EHI
46
Eagle Health Investments
Connecticut
$1.52M – – –
SSA
47
Schonfeld Strategic Advisors
New York
$1.45M -$678K -17,141 -28%
VIG
48
Vienna Insurance Group
Poland
$1.45M +$1.78M +45,000 New
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$1.43M – – –
CAM
50
Cresset Asset Management
Illinois
$1.4M +$1.72M +43,381 New
1
2
3 4 5

CCCC Hedge Fund Activity: Q4 2021 in Review

119 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2021, worth a combined $1.15B — down 25% from $1.54B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CCCC positions and 16 closed out — a net gain of 6 holders — while 42 added to existing stakes and 33 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $24.8M. The largest seller was Jennison Associates, cutting an estimated $18.1M.

  • 119 institutional investors held C4 Therapeutics (CCCC) as of Q4 2021, up from 113 in Q3 2021.
  • Funds reported $1.15B of C4 Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
  • 22 funds opened new C4 Therapeutics positions in Q4 2021 and 16 closed out, a net change of +6 holders.
  • The largest C4 Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $24.8M added.
  • The largest C4 Therapeutics seller in Q4 2021 was Jennison Associates, an estimated $18.1M sold.

Based on aggregated 13F filings for Q4 2021.